肝内胆管癌病理学分型新进展

摘要/Abstract

摘要： 肝内胆管癌传统组织病理学分型主要是根据细胞学形态及细胞起源进行分类,其中95%为腺癌。近年来,有学者们根据组织学特征和细胞起源将肝内胆管癌分为大胆管型和小胆管型,并写入2019版WHO《消化系统肿瘤分类》中,不同的分类方法具有不同的临床特征、组织病理学形态、免疫组化特征、分子特点以及不同的预后,本文就肝内胆管癌两种组织学分型相关研究进展进行综述。

赵燕青, 董辉, 丛文铭. 肝内胆管癌病理学分型新进展[J]. 肝脏, 2022, 27(2): 242-244.

[1] Nakanuma Y, Klimstra DS, Komuta M, et al. Intrahepatic cholangiocarcinoma. WHO Classification of tumours. of digestive system tumours. 5th edition, 2019:254-259.
[2] Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int, 2019, 5:19-31.
[3] Lee AJ, Chun YS. Intrahepatic cholangiocarcinoma: the AJCC/UICC 8th edition updates. Chin Clin Oncol, 2018,7:52.
[4] Theise ND,Nakashima O, Park YN, et al. Combined hepatocellular-cholangiocarcinoma. Bosman FT, Carneiro F, Hruban RH, et al. WHO Classification of Tumours of the Digestive System. 4th edition.Geneva,2010:225-227.
[5] Hayashi A,?Misumi K, Shibahara J, et al. Distinct clinicopathologic and genetic features of 2 intrahepatic cholangiocarcinomas. Am J Surg Pathol, 2016, 40:1021-1030.
[6] 张永杰,丛文铭.胆道病理学.第一版.上海:上海科学技术出版社,2019:128.
[7] Aishima S, Oda Y. Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type. J Hepatobiliary Pancreat Sci, 2015, 22:94-100.
[8] Nakamuma Y, Sato Y, Harada K, et al. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept.World J Hepatol, 2010, 2: 419-427.
[9] Nakamuma Y, Kakuda Y. Pathologic classification of cholangiocarcinoma: new concepts. Best Pract Res Clin Gastroenterol, 2015, 29:277-293.
[10] Sigel CS, Drill E, Zhou Y, et al. Intrahepatic cholangiocarcinomas have histologically distinct small and large duct patterns. Am J Surg Pathol, 2018, 42: 1334-1345.
[11] Akita M, Fujikura K, Ajiki T, et al. Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas. Mod Pathol, 2017,30:986-997.
[12] Aishima S, Kuroda Y, Nishihara Y, et al. Proposal of progression model for intrahepatic cholangiocarcinoma: clinicopathologic differences between hilar type and peripheral type. Am J Surg Pathol, 2007,31:1059-1067.
[13] Rhee H, Ko JE, Chung BA,et al. Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma. Liver Int, 2018, 38:113-124.
[14] Liau JY, Tsai JH, Yuan RH, et al. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. Mod Pathol, 2014, 27:1163-1173.
[15] Arumugam T, Brandt W, Ramachandran V, et al. Trefoil factor 1 stimulates both pancreatic cancer and stellate cells and increases metastasis. Pancreas, 2011, 40:815-822.
[16] Komuta M, Govaere O,Vandecaveye V,et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology,2012,55:1876-1888.
[17] Kim SJ, Akita M, Sung YN, et al. MDM2 amplification in intrahepatic cholangiocarcinomas: its relationship with large-duct type morphology and uncommon KRAS mutations. Am J Surg Pathol, 2018, 42: 512-521.
[18] Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatolgy, 2014, 59: 1427-1434.
[19] Sasaki M, Sato Y, Nakanuma Y. Cholangiolocellular Carcinoma With “Ductal Plate Malformation” Pattern May Be Characterized by ARID1A Genetic Alterations. Am J Surg Pathol, 2019, 43:352-360.
[20] Brunt E, Aishima S, Clavien PA, et al. cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. Hepatology, 2018, 68:113-126.
[21] Sempoux C, Fan C, Singh p, et al. Cholangiocellular carcinoma: an innocent-looking malignant liver tumor mimicking ductular reaction. Semin Liver Dis, 2011, 31:104-110.
[22] Kozaka K, Sasaki M, Fujii T, et al. A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: ‘bile ductular carcinoma'. Histopathology, 2007, 51:390-400.
[23] Wang HL, Kim CJ, Koo J, et al. Practical immunohistochemistry in neoplastic pathology of the gastrointestinal tract, liver, biliary tract, and pancreas. Arch Pathol Lab Med, 2017, 141:1155-1180.
[24] Farshidfar F, Zheng S, Gingras MC, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep, 2017, 19:2878-2880.
[25] Balitzer D,Joseph NM,Ferrell L, et al. Immunohistochemical and molecular features of cholangiolocellular carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma. Mod pathol, 2019, 32:1486-1494.

肝内胆管癌病理学分型新进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	苗慧, 万旭英. 186例肝内胆管癌的预后影响因素分析[J]. 肝脏, 2022, 27(2): 182-184.
[2]	杨怡, 席子涵, 张林颖. 极光激酶B、肿瘤蛋白53在肝细胞癌中的表达及与临床病理特征、预后的关系[J]. 肝脏, 2022, 27(2): 188-192.
[3]	黄嘉敏, 赵霞, 孙宜康, 李宛莹, 苟继周, 周光德, 何清. 何首乌致药物性肝损伤的病理学特点[J]. 肝脏, 2022, 27(1): 20-22.
[4]	何婷婷, 王丽苹, 任璐彤, 崔延飞, 柏兆方, 郭玉明, 宫嫚, 王睿林. 中西药肝损伤临床及病理特征分析[J]. 肝脏, 2021, 26(9): 962-967.
[5]	殷霖霖, 赵思, 张秀华, 季国忠. 混合型肝细胞-胆管癌的诊疗进展[J]. 肝脏, 2021, 26(7): 720-723.
[6]	曹欣, 邓浩辉, 肖艳华, 余卫华, 陈燕清. 96例ALT正常慢性HBV感染者进展影响因素及肝脏病理学分析[J]. 肝脏, 2021, 26(7): 750-753.
[7]	侯亚萍, 张小晶, 李婷. 原发性肝癌患者LncRNA-MEG3表达与临床病理特征及预后的关系[J]. 肝脏, 2021, 26(7): 757-760.
[8]	张均维, 黄旭东, 蔡弟, 王桂浩. 巨大肝血管瘤患者临床特征及不同介入栓塞材料的价值观察[J]. 肝脏, 2021, 26(7): 788-791.
[9]	王晴晴, 彭宇辉, 唐艳芳. 特发性非肝硬化性门静脉高压症的临床及病理特点分析[J]. 肝脏, 2021, 26(3): 291-295.
[10]	洪晓绿, 徐沛演, 潘小平. CYP2E1和CYP1A1基因型与广州北部地区人群HBV易感性间的相关性分析[J]. 肝脏, 2021, 26(2): 131-135.
[11]	岳秀娟, 李庆, 王珊珊, 陈德喜, 石英. 786例慢性乙型肝炎患者恩替卡韦基因型耐药突变及特征分析[J]. 肝脏, 2021, 26(12): 1344-1347.
[12]	唐文静, 朱婷, 方静, 王松平. 实时剪切波弹性成像对不同程度儿童肝纤维化的诊断价值[J]. 肝脏, 2021, 26(12): 1356-1359.
[13]	刘香丽, 张丽慧, 柴婕, 杨晓青, 王欢, 刘雪涛, 赵文霞. 40例不明原因肝损伤患者的临床病理分析[J]. 肝脏, 2021, 26(12): 1387-1390.
[14]	周梅月, 全卉, 陈贺宁, 江宇泳. Gao-Binge酒精性肝病模型小鼠的损伤特点[J]. 肝脏, 2021, 26(12): 1407-1410.
[15]	李爱敏, 曹斌. 原发性胆汁性胆管炎患者病理分期与生化指标的相关性分析[J]. 肝脏, 2021, 26(1): 81-83.